Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
TipRanksApr 17 16:05 ET
Express News | BioRestorative Therapies Inc : Maxim Group Cuts Target Price to $6 From $10
Moomoo 24/7Apr 17 01:07 ET
Biotech Catches Major Premarket Bid Following FDA Clearance
YolowireApr 16 10:07 ET
Express News | BioRestorative Therapies Shares up 9.5% After U.S. FDA Clears Change to Cell Therapy's Mid-Stage Study
Moomoo 24/7Apr 16 09:36 ET
BioRestorative Therapies Says US FDA Clears Amended Protocol for Phase 2 Cell Therapy Trial
BioRestorative Therapies (BRTX) said Tuesday that the US Food and Drug Administration has cleared an amendment to the protocol of the current phase 2 trial of its cell therapy candidate, BRTX-100, to
MT NewswiresApr 16 08:56 ET
Market-Moving News for April 16th
CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus On
BenzingaApr 16 08:36 ET
Why BioRestorative Therapies Is Rising In Pre-market?
RTTNewsApr 16 08:15 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersDynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. BioRestorative Therapies (NASDAQ:BRTX) shares rose 23.4
BenzingaApr 16 08:07 ET
Express News | BioRestorative Therapies Shares Are Trading Higher After the Company Announced FDA Clearance of Its Phase 2 BRTX-100 Clinical Study Protocol Amendment
Moomoo 24/7Apr 16 07:58 ET
Express News | BioRestorative Therapies Inc - Protocol Amendment Removes Saline Injection in Control Arm of Study and Replaces It With a Sham Injection
Moomoo 24/7Apr 16 07:45 ET
Express News | BioRestorative Therapies Announces FDA Clearance of Phase 2 Brtx-100 Clinical Study Protocol Amendment
Moomoo 24/7Apr 16 07:45 ET
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration ("FDA") has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company's lead cell therapy candidate, in treating chronic lumbar disc disease ("cLDD").
GlobeNewswireApr 16 07:45 ET
10 Micro-Cap Healthcare Stocks Insiders Are Buying
Yahoo FinanceApr 14 15:00 ET
Degenerative Disc Disease Drug Pipeline Research Report 2024 Featuring Spine BioPharma, Angitia Biopharmaceuticals, Mesoblast, BioRestorative Therapies, and DiscGenics, Inc.
Yahoo FinanceApr 11 09:08 ET
Dominari Holdings And 2 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed lower by over 400 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
BenzingaApr 11 08:41 ET
Biorestorative Therapies(BRTX.US) Officer Buys US$10,229.32 in Common Stock
$Biorestorative Therapies(BRTX.US)$ Officer Silva Francisco purchased 8,308 shares of common stock on Apr 8, 9, 2024 at an average price of $1.23 for a total value of $10,229.32.Source: Announcement W
moomoo NewsApr 10 17:57 ET
BioRestorative Therapies Stock up on Partnership With Galen Patient Recruitment
Seeking AlphaApr 8 09:19 ET
Microstrategy, Apartment Income REIT, Marathon Digital Among Premarket Gainers' Pack
Seeking AlphaApr 8 09:10 ET
PERI, ITRM and CADL Among Pre-market Losers
Seeking AlphaApr 8 08:23 ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersLongeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. The market value of their outstanding shares is at $9.6 million. PetVivo Hldgs (NASDAQ:PETV)
BenzingaApr 8 08:09 ET
No Data
No Data